The role of basiliximab in the evolving renal transplantation immunosuppression protocol
Paola Salis, Chiara Caccamo, Roberto Verzaro, Salvatore Gruttadauria, Mary ArteroDivision of Nephrology and Division of Abdominal Transplantation, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, ItalyAbstract: Basiliximab is a chimeric mouse-human monoclonal antibo...
Guardado en:
Autores principales: | Paola Salis, Chiara Caccamo, Roberto Verzaro, Salvatore Gruttadauria, Mary Artero |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/19c5284fbc23402b90ca3fa69495bc19 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients
por: Locke JE, et al.
Publicado: (2011) -
Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation
por: Junichiro Sageshima, et al.
Publicado: (2009) -
Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
por: Martina Koch, et al.
Publicado: (2009) -
Basiliximab impairs regulatory T cell (TREG) function and could affect the short-term graft acceptance in children with heart transplantation
por: Jacobo López-Abente, et al.
Publicado: (2021) -
Relationship of transitional regulatory B and regulatory T cells and immunosuppressive drug doses in stable renal transplant recipients
por: Eman H Ibrahim, et al.
Publicado: (2021)